Search - Browse Site

Why Investors Should Consider Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) DON'T MISS THIS OPPORTUNITY A Strategic Pivot into High-Growth Sectors Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) is undergoing a transformative shift its origins as a biopharmaceutical company to a diversified entity embracing cutting-edge technologies. The company's recent initiatives include the launch of the COEP Venture Group, aimed at investing in disruptive technologies such as artificial intelligence (AI) and robotic process automation (RPA) . This strategic pivot positions Coeptis to capitalize on high-growth sectors beyond traditional pharmaceuticals.( investors.coeptistx.com , stockinsights.ai ) Innovative Cell Therapy Platforms Despite its diversification, Coeptis continues to advance its biopharmaceutical endeavors. The company is developing innovative cell therapy platforms for cancer treatment, including CD38-GEAR-NK, an autologous, gene-edited natural killer (NK) cell-based therapeutic, and CD38-Diagnostic, an in vitro screening tool designed to identify patients likely to benefit from targeted anti-CD38 monoclonal antibody therapies . These platforms have the potential to disrupt conventional treatment paradigms and improve patient outcomes.( Nasdaq , www.alphaspread.com , Annual Reports ) Strategic Merger with Z Squared Inc. In a significant move, Coeptis has entered into a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. This merger will make Z Squared a wholly-owned subsidiary of Coeptis, with plans to spin out its biopharmaceutical operations and rebrand as Z Squared, Inc. The combined company aims to enhance Dogecoin mining capabilities and capitalize on the growing digital asset market .( Nasdaq ) Robust Financial Backing Coeptis has demonstrated strong financial support through successful funding rounds. The company recently closed a $10 million Series A Preferred financing round, reinforcing its commitment to technological innovation and AI integration ( PR Newswire ). Additionally, a prior $4.3 million Series A Preferred offering was led by CJC Investment Trust, an entity controlled by board member Christopher Calise ( PR Newswire ). INVESTMENT ALERT Investment Highlights Diversified Portfolio : Transitioning into high-growth sectors like AI, RPA, and digital assets. Innovative Therapies : Developing next-generation cell therapy platforms for oncology. Strategic Partnerships : Merging with Z Squared Inc. to enter the cryptocurrency mining space.( Nasdaq ) Financial Strength : Secured substantial funding to support growth and innovation initiatives. BUY NOW Call your Broker now! Learn More For more information, visit the Investor Relations page of Coeptis Therapeutics Holdings Inc. DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have not received any compensation regarding the profiling of Coeptis Therapeutics Holdings Inc.   (Nasdaq: COEP).  It is important to note that we do not own any shares in COEP: NASDAQ .

Invest in GPO Plus, Inc. (OTCQB: GPOX) Revolutionizing Distribution with AI-Driven Solutions Why Invest in GPOX? - HERE IS ONE COMPANY TO KEEP YOUR EYE ON! GPO Plus, Inc. (OTCQB: GPOX) is an innovative distributor transforming the convenience store and gas station sectors through its AI-powered Direct Store Delivery (DSD) model. With a focus on high-demand consumer products and a commitment to operational excellence, GPOX offers investors a unique opportunity in a rapidly growing market. Key Investment Highlights Explosive Revenue Growth : Achieved a 560% year-over-year revenue increase, reaching $4.35 million in annual revenue. AI-Powered Operations : Deployed PRISM+, an AI-driven platform optimizing delivery routes, inventory management, and operational efficiency. Strategic Expansion : Added 52 TXB convenience store locations in Texas, with plans to expand to 2,000 retail locations. Scalable Business Model : Focused on the fragmented 15%-20% of convenience store products, representing a $50 billion market opportunity. Innovation at the Core GPOX leverages its proprietary technology platform, PRISM+, to streamline operations and enhance decision-making. This AI-driven system enables precise inventory tracking, optimized delivery routes, and real-time analytics, reducing overhead costs and increasing profitability. Growth Strategy GPOX's growth strategy includes: Climate-Controlled Warehousing : Upgrading facilities to support a broader product range and increase annual revenues by $3 to $5 million. Retail Network Expansion : Utilizing existing delivery routes to add over 2,000 new retail locations, focusing on underserved markets. Call Center Sales Team : Establishing a dedicated team to reach independent stores, aiming for monthly sales of $50,000 to $100,000 per seat. Diverse Product Portfolio GPOX operates multiple Group Purchasing Organizations (GPOs), each focusing on high-demand sectors: NutraGPO™ : Nutraceuticals and wellness products. CBDGPO™ : Premium CBD and hemp products. SmokeGPO™ : Specialty vape and smoke retail products. MushroomGPO™ : Functional and adaptogenic mushrooms. SmartGPO™ : Tech-forward products for modern consumers. Financial Performance Q2 2023 Revenue : $1.21 million, a 25% increase from the previous quarter. Annual Revenue : $4.35 million, marking a 560% year-over-year growth . Investor Resources Investor Deck (PDF) Latest Earnings & Filings Ready to Invest? Join us in revolutionizing distribution and seizing opportunities in high-growth markets.   Invest in GPOX Today INVEST WITH US, WHERE OPPORTUNITY MEETS GROWTH Investors are Welcome INVEST IN YOUR FUTURE - CALL YOUR BROKER NOW Given these factors, investing in GPO PLUS might be a strategic move for those looking to be part of the next wave of technological innovation. DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Spectral Capital Corp.  (OTCQB: GPOX) starting on April 15, 2025. It is important to note that we do not own any shares in GPOX: OTCQB.

A Bold Step into the Future of Biopharmaceutical Innovation In a world where groundbreaking medical advancements are shaping the future of healthcare, Quantum BioPharma Ltd (NASDAQ: QNTM)  stands at the forefront of a revolution in neurodegenerative and inflammatory disease treatments. With a clear mission to develop novel therapies for some of the most pressing medical conditions, Quantum BioPharma is capturing the attention of investors and healthcare professionals alike. A Visionary Company with a Groundbreaking Approach Quantum BioPharma is not just another biopharmaceutical company; it is a visionary leader in the quest to find solutions for conditions that have long been considered difficult to treat. The company’s innovative approach, spearheaded by its flagship product Lucid-MS , is set to redefine the treatment landscape for multiple sclerosis (MS) , one of the most debilitating neurodegenerative diseases in the world. MS affects millions of people globally, and current treatments focus primarily on symptom management, leaving a significant gap in curing or reversing the disease. Quantum BioPharma’s Lucid-MS , a proprietary compound, is designed to target the very heart of MS by addressing myelin degradation. In preclinical trials, Lucid-MS  has shown the potential to not only halt the progression of MS but also reverse some of the damage caused by the disease. This level of innovation has the potential to change the lives of millions who currently face a future without hope for a cure. Strong Clinical Progress and Market Potential Quantum BioPharma has already made significant strides in advancing Lucid-MS  toward commercialization. Having completed Phase-1 clinical trials successfully, the company is now positioned to move into subsequent phases of development. This progression signals confidence in the efficacy and safety of the treatment, with the prospect of reaching patients in desperate need of a novel therapeutic solution. The global market for multiple sclerosis treatments is valued at billions of dollars and continues to grow as new patient diagnoses increase. With its breakthrough therapy, Lucid-MS , Quantum BioPharma is tapping into this vast market, which promises not only to bring relief to patients but also significant revenue opportunities for the company. Diversifying into Wellness with Unbuzzd™ But Quantum BioPharma’s ambition doesn’t stop at neurodegenerative treatments. The company has also ventured into the burgeoning wellness market with its innovative product, unbuzzd™ . This unique, scientifically developed beverage is designed to support recovery after alcohol consumption, helping individuals detoxify, restore mental clarity, and improve overall well-being. With unbuzzd™ , Quantum BioPharma is addressing a market that is both diverse and rapidly expanding. The global wellness industry is valued in the trillions, and consumer interest in products that promote health and well-being is at an all-time high. Unbuzzd™ taps into a growing consumer trend seeking functional beverages that go beyond traditional soft drinks and wellness supplements, positioning Quantum BioPharma as a player in the wellness space alongside its biopharmaceutical innovations. A Talented Team Driving Change Behind every groundbreaking innovation is a team of passionate and dedicated individuals. Quantum BioPharma boasts a leadership team that combines decades of experience in biopharmaceutical development, science, and wellness. With a track record of success in launching novel products, the team at Quantum BioPharma is equipped to tackle the challenges ahead and drive the company to new heights. The Investment Opportunity: A Bright Future Ahead For investors, Quantum BioPharma offers an exciting opportunity to be part of a company poised for significant growth in multiple high-demand markets. The combination of cutting-edge biopharmaceutical development in neurodegenerative disease treatments, alongside a foray into the wellness industry, positions Quantum BioPharma as a dynamic and multifaceted company with vast potential. Quantum BioPharma's strong pipeline, proven clinical progress, and leadership team provide a solid foundation for future success. As the world continues to demand new and more effective treatments for diseases like multiple sclerosis and a greater focus on wellness solutions, Quantum BioPharma stands to capture a leading position in both the biopharma and wellness industries. For investors looking for a company with vision, innovation, and an ambitious plan for the future, Quantum BioPharma Ltd (NASDAQ: QNTM)  offers a chance to be part of something truly transformative. With significant growth potential, an expanding product portfolio, and an unwavering commitment to improving patient lives, Quantum BioPharma is a company worth watching. Invest in Quantum BioPharma  today and be part of a brighter, healthier future. About: Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit www.vanderbiltreport.com .   Contact Us Sales Snap Media Group/Vanderbiltreport.com 1050 US Hwy 1 Key West, Florida 33040 Email: info@vanderbiltreport.com Web: VanderbiltReport.com

Why Totaligent, Inc. (OTC: TGNT) is the Exciting Investment Opportunity You Haven't Heard About Yet Totaligent, Inc. is an innovative technology company that harnesses the power of big data through a variety of cutting-edge platforms. From email and SMS to Social Media and programmatic advertising, we utilize a range of tools including short-code and push notifications to deliver highly targeted digital marketing solutions for organizations of all sizes. At Totaligent (OTC: TGNT) , we are revolutionizing the way businesses connect with their target audience. Our person-based digital marketing platform empowers organizations to leverage their data and tap into new sources to promote their products, services, and brands with unprecedented efficiency. An early-stage AI disruptor with massive potential—invest now and ride the wave of intelligent automation. Totaligent’s AI ecosystem is built for long-term growth, offering unparalleled efficiency and data-driven advantage M Market Opportunity and Highlights Totaligent, Inc. (OTC: TGNT) is a technology company specializing in person-based digital marketing services for companies and individuals in the United States. The company offers managed campaigns to publicly traded companies and political candidates. In 2023, Totaligent reported a significant revenue increase to $731,679, up 3,652% from $19,500 in the previous year . The company also reduced its losses by 32% to $402,170 in 2023. As of February 14, 2025, Totaligent's stock price was $0.0400, reflecting a 90.48% increas e from the previous close. The company's market capitalization stands at $3.65 million, with 172.91 million shares outstanding. In December 2024, Totaligent successfully completed PCAOB audits for fiscal years 2022 and 2023, resuming SEC reporting as a voluntary filer. Investors may find Totaligent appealing due to its substantial revenue growth, improved financial performance, and commitment to regulatory compliance. why investors should invest in Totaligent, Inc, https://www.totaligent.com/investors/ Totaligent, Inc. (OTC: TGNT) is a technology company specializing in AI-powered, person-based digital marketing solutions. The company has recently achieved significant milestones that may appeal to investors: Totaligent, Inc. (OTC: TGNT) stands out not just as a digital marketing firm, but as a leader in person-based marketing innovation. Their focus on personalization, coupled with advanced technology and a proven track record, offers a remarkable investment opportunity that many may still overlook. For investors seeking a blend of security, growth potential, and alignment with market trends, Totaligent presents a noteworthy option. As the digital marketing landscape expands, investing in a company at the forefront of this evolution could yield substantial dividends. Invest in Totaligent today and be part of the exciting future of marketing! DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $1,500 from Totaligent, Inc. (Nasdaq: TGNT)  starting on Frebuary 14, 2025. It is important to note that we do not own any shares in TGNT: NASDAQ .

HERE IS ONE COMPANY TO KEEP YOUR EYE ON! EXPERIENCE THE POWER OF: TC BIOPHARM (NASDAQ: TCBP) CALL YOUR BROKER NOW Investing in TC BioPharm (Nasdaq: TCBP) can offer several highlights, particularly for those interested in the biotechnology sector. Here are some key points to consider: 1. Innovative Therapies    - TC BioPharm focuses on developing cell therapies, particularly for cancer treatment and other serious diseases. Their lead product, TCB-001, is designed for patients with hematologic malignancies.   2. Strong Pipeline    - The company has a robust pipeline of therapies in various stages of clinical development, which can provide multiple avenues for growth and potential revenue. 3. Experienced Management Team    - A seasoned management team with expertise in biotechnology and pharmaceuticals can enhance investor confidence in the company’s strategic direction and execution. 4. Strategic Partnerships    - Collaborations with academic institutions and other biopharmaceutical companies may provide additional resources, expertise, and validation for their products. INVEST WITH US, WHERE OPPORTUNITY MEETS GROWTH 5. Market Potential    - The market for cancer therapies is substantial and growing, driven by an increasing prevalence of cancer and a demand for more effective treatments. 6. Regulatory Progress    - Progress in regulatory approvals can be a significant catalyst for stock price appreciation. Positive results from clinical trials can lead to accelerated pathways for approval. 7. Investment in Research and Development    - A commitment to R&D can indicate potential for innovation and long-term growth, making it an attractive option for long-term investors. 8. Growing Interest in Cell Therapies    - As the field of cell therapies continues to expand, TC BioPharm is well-positioned to capitalize on this trend, which may enhance their market standing. 9. Potential for Partnerships/Acquisitions    - As the company develops its therapies, there may be opportunities for partnerships or acquisitions that could further enhance its value. 10. Investor Sentiment    - Positive news flow, successful clinical trial results, or strategic business developments can lead to favorable investor sentiment and stock performance. INVEST IN YOUR FUTURE - CALL YOUR BROKER NOW TRANSFORMING YOUR PORTFOLIO ONE TEST TRAIL AT A TIME! TAKE ACTION NOW AND CALL YOUR BROKER Unlock Your Rewards and Receive Medicus Tokens   Join Vanderbiltreport.com for all your Early Alerts S napmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Citius Pharmaceuticals, Inc. (Nasdaq: TCBP)  starting on Sept 15, 2024. It is important to note that we do not own any shares in TCBP: NASDAQ .

Spectral Capital Corporation (OTCQB: FCCN)  is a diversified holding company focused on acquiring and managing businesses in emerging sectors. The company seeks opportunities in industries such as technology, telecommunications, and other growth-driven markets. With a strategy centered on long-term value creation, Spectral Capital aims to maximize returns for its shareholders by leveraging its expertise and resources to support the development and expansion of its portfolio companies. By capitalizing on market trends and operational synergies, Spectral Capital strives to build a strong, sustainable business platform. HERE IS ONE COMPANY TO KEEP YOUR EYE ON! Investing in Spectral Capital, a publicly traded Deep Quantum Technology Platform Company, could offer several compelling reasons for potential investors: 1.       Cutting-Edge Technology : Spectral Capital is working at the forefront of quantum computing, a field that promises to revolutionize industries like healthcare, finance, cybersecurity, and logistics. As quantum computing moves from theoretical to practical applications, companies leading this charge stand to gain significant competitive advantages. TECHNOLOGY PLATFORMS Quantum Bridge - Noot - Monitor - Vogon - TVF - IBA 2.       Scalability Potential : By focusing on bridging the gap between quantum and classical computing, Spectral Capital is addressing a critical challenge in making quantum technology practical and scalable. Their mission to create a foundation for the next generation of technology positions them to be a key player as this transition takes place. 3.       Disruption Across Industries : As quantum computing matures, it will disrupt existing technologies. Spectral Capital’s innovations could pave the way for breakthroughs that reshape how industries operate, creating new opportunities for investors. The company's ability to integrate quantum technology with current computing systems can provide a competitive edge in the market. 4.       Strategic Market Position : Being publicly traded means that Spectral Capital is more transparent, allowing investors to assess its performance and growth potential more easily than private startups. Its positioning in a niche but rapidly expanding sector makes it an attractive choice for forward-thinking investors. INVEST WITH US, WHERE OPPORTUNITY MEETS GROWTH January 29, 2025 5.       Long-Term Growth : The development of quantum technologies is still in its early stages, meaning that long-term investments in companies like Spectral Capital have the potential for substantial returns as the market grows and matures. With ongoing investments in research and development, they’re positioned to lead this future transformation. 6.       Diverse Applications : Quantum computing could impact everything from drug discovery and materials science to artificial intelligence and cryptography. Spectral Capital’s work could have wide-reaching implications, which could mean diverse revenue streams and growth opportunities. 7.       Attractive Industry Outlook : The quantum computing market is expected to see substantial growth over the coming decades, with some estimates predicting a market worth hundreds of billions by the 2030s. Investors who enter the space early could see significant returns as the technology matures and adoption increases. Investors are Welcome INVEST IN YOUR FUTURE - CALL YOUR BROKER NOW Given these factors, investing in Spectral Capital might be a strategic move for those looking to be part of the next wave of technological innovation. The company’s ability to merge quantum and classical computing is a unique opportunity to capitalize on the evolution of technology at the highest level. DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Spectral Capital Corp.  (OTCQB: FCCN) starting on January 12, 2025. It is important to note that we do not own any shares in FCCN: OTCQB.

Prenetics (NASDAQ: PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world’s most comprehensive consumer DNA test. Our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics’ units synergistically enhances our global impact on health, truly embodying our commitment to enhancing life through science.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet). Allogeneic Immune Cell Generation Platform   Ability to manufacture immune effector cells (natural killer (NK) cells, macrophages) from cord blood derived CD34+ cells Truly universal – no HLA matching required Clinically Tested: Unmodified NK cells have been investigated in two phase 1 clinical trials   Universal SNAP-CAR   Antigen agnostic chimeric antigen receptor (CAR) platform Universal SNAP-CAR construct binds to tagged antibodies directing antigen specificity and allowing for use of multiple antigens in the same indication SNAP-CAR expression in a universal immune effector cell results in the ability to use ONE off-the-shelf SNAP-CAR cell bank for use with selected tagged antibodies across multiple indications such as hematological malignancies, solid tumors, and autoimmune diseases   GEAR Platform   GEAR: “Gene-Edited Antibody Resistant” cell engineering technology Gene editing of immune effector cells to prevent fratricide when using therapeutic antibodies GEAR editing does not impact normal function of non-modified cells   Development & Clinical Collaborations   University of Pittsburgh Karolinska Institute Deverra Therapeutics Fred Hutch Cancer Center Duke Cancer Institute Novant Health

(CSE: ARGO) (OTC: ARLSF) Living soils technology refers to agricultural practices that focus on enhancing and maintaining the health and vitality of soil ecosystems. The concept revolves around the idea that healthy soil is a living organism itself, teeming with diverse microbial life, insects, worms, and other organisms. We are currently at a one-year high and have the potential to increase by five times! NOW IS THE TIME TO BUY Key components of living soil technology include: Organic Matter : Adding organic matter such as compost, crop residues, and cover crops to the soil to improve its structure, fertility, and water-holding capacity. Microbial Diversity : Promoting the growth of beneficial microorganisms like bacteria, fungi, and protozoa that play crucial roles in nutrient cycling, disease suppression, and soil health. Minimal Disturbance : Minimizing tillage and other practices that disrupt soil structure and disturb the soil microbiome. Crop Rotation : Rotating crops to prevent soil depletion and promote biodiversity in the soil ecosystem. Soil Monitoring : Regularly assessing soil health parameters such as nutrient levels, microbial activity, and soil structure to guide management decisions. Biological Amendments : Using microbial inoculants, biofertilizers, and other biological amendments to enhance soil fertility and promote plant growth. Overall, living soils technology aims to create a balanced and resilient soil ecosystem that supports healthy plant growth, reduces the need for synthetic inputs, and improves the long-term sustainability of agricultural systems. Biomass-to-Graphene Turning Waste Biomass into High-Quality Graphene: A Revolution for Farming and Industry Biochar A carbon-rich organic material is generated in the absence of oxygen using a reactor at temperatures higher than 500°C. The process called pyrolysis converts organic biomass (such as wood chips, crop residue or manure) into carbon-rich biochar, a specific type of charcoal. DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Argo Living Soils  ((CSE: ARGO) (OTC Pink: ARLSF) starting on January 12, 2025. It is important to note that we do not own any shares in(CSE: ARGO) (OTC Pink: ARLSF).

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA:0K91) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. They are currently working on Lucid-MS, a compound that has shown promise in treating multiple sclerosis. They also developed unbuzzd™ and spun out an OTC version to Celly Nutrition Corp., in which Quantum BioPharma retains a 25.71% ownership stake. Upgrade your investments T he global hangover cure products market size was valued at USD 2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2023 to 2030 when it is expected to reach a value of USD C.2 billion. Until now, there is no effective product that  reverses  the effects of alcohol efficiently. Restores mental alertness and improves cognition post-alcohol consumption in an average of 15-30 minutes. Proprietary formulation of extracts, vitamins, and minerals helps with liver and brain function. Ingredients help reduce BAC faster than what the body would do naturally. You invested in a night out You invested in drinking You invested so much, you have a hangover Invest in Unbuzzd - Quantum BioPharma Ltd. (NASDAQ: QNTM) Where innovation meets returns, invest in QNTM Quantum Biopharma is known for its innovative approach in the biopharmaceutical sector, focusing on developing therapies that harness biological processes. Here are some potential business highlights for a company like Quantum Biopharma:   Innovative Therapies:  Developing cutting-edge biopharmaceuticals targeting unmet medical needs, particularly in areas like oncology, autoimmune diseases, or infectious diseases.   Strategic Partnerships: Collaborations with research institutions and pharmaceutical companies to enhance R&D capabilities and expedite the development process.    Intellectual Property:   Strong portfolio of patents that protects proprietary technologies and therapies, ensuring a competitive edge in the market.   Funding and Investment:   Securing significant funding from venture capital, grants , or partnerships that support ongoing research and development initiatives.   Regulatory Milestones:   Achieving key regulatory approvals that pave the way for market entry of new products.   Market Expansion:  Plans for global market entry or expansion into new therapeutic areas, broadening the potential customer base.   Expertise and Leadership:  A strong leadership team with deep expertise in biopharma, guiding the company through its growth phases.    These highlights would position Quantum Biopharma LTD as a forward-thinking player in the biopharmaceutical landscape. For the most accurate and detailed information, please refer to the company’s latest reports or press releases. Invest with QNTM, where opportunity meets growth Invest today – Enjoy tomorrow Call your Broker Now DISCLAIMER Snapmediagroup.net and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Quantum BioPharma Ltd  (Nasdaq: QNTM)  starting on October 1, 2024. It is important to note that we do not own any shares in QNTM: NASDAQ .

Mangoceuticals, Inc. Mangoceuticals, Inc. (NASDAQ: MGRX) , also known as MangoRx, is a Dallas-based company specializing in men's health and wellness products delivered through a secure telemedicine platform. Established in 2021, the company offers treatments for erectile dysfunction (ED) under the "Mango" brand and hair loss solutions under the "Grow" brand. These products are accessible online via their website, MangoRx.com . Call your Broker now! Upgrade your investments Find out more below Invest in Mangoceuticals Inc. (NASDAQ: MGRX) Invest with MGRX where opportunity meets growth WHY MAN UP AND INVEST 1.      Expanding Market in Men’s Health & Wellness Mangoceuticals operates in the rapidly growing men’s health and wellness industry, specifically targeting the expanding market for erectile dysfunction (ED) and performance-enhancing products. With increasing consumer awareness and demand for convenient, telemedicine-driven solutions, the company is well-positioned for strong growth. 2.      Unique Branding & Direct-to-Consumer Approach The company differentiates itself with bold marketing strategies and a unique branding approach. Its flagship product, "Mango," offers an innovative take on ED medication, leveraging online sales and direct-to-consumer distribution to maximize reach and profitability. 3.      High-Growth Potential & Scalable Business Model With a digital-first strategy, Mangoceuticals can rapidly scale its business without the overhead costs of traditional pharmaceutical sales. The company is expanding its product line and exploring additional opportunities in the wellness and lifestyle enhancement markets. 4.      Strategic Marketing & Celebrity Partnerships The company actively engages in strategic marketing efforts, including influencer partnerships, sports sponsorships, and collaborations with high-profile media platforms. These initiatives enhance brand visibility and create a strong customer base. 5.      Attractive Investment in a Niche Market Unlike many competitors in the broader pharmaceutical space, Mangoceuticals focuses on a specialized niche with strong consumer demand. This targeted approach allows for high-margin sales and significant long-term revenue potential, making it an appealing investment opportunity. Invest today – Enjoy tomorrow Call your Broker Now DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Mangoceuticals, Inc . (Nasdaq: MGRX)  starting on February 2, 2025. It is important to note that we do not own any shares in MGRX: NASDAQ .

NAPC Defense, Inc. (BLIS): Fully Licensed Veteran-Owned Leaders in Armament Sales and Production NAPC Defense, Inc. (formerly known as Treasure & Shipwreck Recovery, Inc.), trading as (OTCPK: BLIS), announces that it has completed the change of name with the State of Nevada and registration with the State of Florida, as well as a new website at www.NAPCDefense.com . It is also finalizing its application with FINRA to effect all additional merger terms announced in the March 27, 2024 press release. NAPC Defense, Inc. owns defense and construction contracting firm Native American Price Constructors, LLC.